Clinical trial results:
A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma

Summary

EudraCT number	2011-001360-21
Trial protocol	GB DE CZ ES PL
Global end of trial date	22 February 2014

Results information

Result version number	v2 (current)
This version publication date	22 March 2017
First version publication date	15 April 2016
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	CD-RI-CAT-354-1049

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01402986
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	MedImmune, LLC
Sponsor organisation address	Milstein Building, Granta Park,, Cambridge, United Kingdom, CB21 6GH
Public contact	Meena Jain, MB BChir, Director, Clinical Development,, MedImmune, LLC, JainM@medimmune.com
Scientific contact	Meena Jain, MB BChir, Director, Clinical Development,, MedImmune, LLC, JainM@medimmune.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 February 2014
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	22 February 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate two subcutaneous (SC) treatment regimens of 300 milligram (mg) tralokinumab compared with placebo by assessing the effect on asthma exacerbation rate over 52 weeks in adults with uncontrolled, severe asthma requiring high-dose inhaled corticosteroids (ICS) and long-acting beta2-agonists (LABA), with or without additional asthma controller medications.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Participating participant signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 August 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	6 Months
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 25
Country: Number of subjects enrolled	Canada: 10
Country: Number of subjects enrolled	France: 42
Country: Number of subjects enrolled	Spain: 11
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	Germany: 37
Country: Number of subjects enrolled	Poland: 23
Country: Number of subjects enrolled	Philippines: 60
Country: Number of subjects enrolled	Mexico: 30
Country: Number of subjects enrolled	Argentina: 40
Country: Number of subjects enrolled	Russian Federation: 33
Country: Number of subjects enrolled	Chile: 22
Country: Number of subjects enrolled	Czech Republic: 20
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 32

Country: Number of subjects enrolled	Japan: 64
Worldwide total number of subjects	452
EEA total number of subjects	136

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	397
From 65 to 84 years	55
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 689 participants were screened out of which 452 participants were randomized into this study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo, Q2W - Cohort 1

Arm description:

Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.

Arm type	Placebo
Investigational medicinal product name	Placebo Q2W
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.

Arm title	Tralokinumab 300 mg, Q2W - Cohort 1

Arm description:

Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.

Arm type	Experimental
Investigational medicinal product name	Tralokinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.

Arm title	Placebo, Q2/4W - Cohort 2

Arm description:

Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.

Arm type	Placebo

Investigational medicinal product name	Placebo, Q2/4W
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.

Arm title	Tralokinumab 300 mg, Q2/4W - Cohort 2

Arm description:

Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.

Arm type	Experimental
Investigational medicinal product name	Tralokinumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.

Number of subjects in period 1	Placebo, Q2W - Cohort 1	Tralokinumab 300 mg, Q2W - Cohort 1	Placebo, Q2/4W - Cohort 2
Started	76	150	75
Completed	67	135	67
Not completed	9	15	8
Adverse event, serious fatal	-	-	-
Consent withdrawn by subject	7	10	7
Unspecified	2	5	1
Lost to follow-up	-	-	-

Number of subjects in period 1	Tralokinumab 300 mg, Q2/4W - Cohort 2
Started	151
Completed	129
Not completed	22
Adverse event, serious fatal	2
Consent withdrawn by subject	13
Unspecified	6
Lost to follow-up	1

Baseline characteristics

Reporting groups	
Reporting group title	Placebo, Q2W - Cohort 1
Reporting group description:	
Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.	
Reporting group title	Tralokinumab 300 mg, Q2W - Cohort 1
Reporting group description:	
Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.	
Reporting group title	Placebo, Q2/4W - Cohort 2
Reporting group description:	
Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.	
Reporting group title	Tralokinumab 300 mg, Q2/4W - Cohort 2
Reporting group description:	
Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.	

Reporting group values	Placebo, Q2W - Cohort 1	Tralokinumab 300 mg, Q2W - Cohort 1	Placebo, Q2/4W - Cohort 2
Number of subjects	76	150	75
Age categorical Units: Subjects			
Age Continuous | Units: years arithmetic mean standard deviation	 48.8 ± 12.1	 49.7 ± 12.2	 51.7 ± 13.6
Gender, Male/Female Units: participants			
Female	51	100	46
Male	25	50	29

Reporting group values	Tralokinumab 300 mg, Q2/4W - Cohort 2	Total	
Number of subjects	151	452	
Age categorical Units: Subjects			
Age Continuous | Units: years arithmetic mean standard deviation	 50.5 ± 11.8	 -	
Gender, Male/Female Units: participants			
Female	100	297	
Male	51	155	

End points

End points reporting groups

Reporting group title	Placebo, Q2W - Cohort 1
Reporting group description:	
Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.	
Reporting group title	Tralokinumab 300 mg, Q2W - Cohort 1
Reporting group description:	
Participants received tralokinumab 300 milligram (mg) subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.	
Reporting group title	Placebo, Q2/4W - Cohort 2
Reporting group description:	
Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.	
Reporting group title	Tralokinumab 300 mg, Q2/4W - Cohort 2
Reporting group description:	
Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.	
Subject analysis set title	Placebo Total
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for a total of 16 doses up to 38 weeks.	
Subject analysis set title	Intent-to-treat (ITT) population
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
The ITT population included all participants who were randomized into the study.	

Primary: Annual Asthma Exacerbation Rate (AER)

End point title	Annual Asthma Exacerbation Rate (AER)[1]
End point description:	
The annual asthma exacerbation rate (AER) in participants, was calculated as the total number of observed exacerbations in each group up to week 53, divided by total duration of person-year follow-up in each group. An asthma exacerbation defined as a progressive increase of asthma symptoms (cough, wheeze, chest tightness, and/or shortness of breath) that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids (tablets, suspension or injection) or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed or administered by the investigator or healthcare provider; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 days. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The intent-to-treat (ITT) population included all participants who were randomized into the study.	
End point type	Primary
End point timeframe:	
Week 1 up to Week 53	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: AER events/person-year				
number (confidence interval 95%)	0.91 (0.76 to 1.08)	0.97 (0.81 to 1.14)	0.9 (0.75 to 1.08)	

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

The 95 percent (%) confidence interval (CI) for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 versus [vs] more than [>] 2 but less than or equal to [=<] 6), atopic asthma status (atopic/non-atopic), chronic oral corticosteroid (OCS) use (presence vs absence) and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.709
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	1.31

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs > 2 but =< 6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.904
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.02

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	1.46

Secondary: Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53

End point title	Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53[2]

End point description:

Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: liters				
arithmetic mean (standard error)				
Pre-bronchodilator: Baseline (n=147,146,146)	1.922 (± 0.056)	1.934 (± 0.059)	1.926 (± 0.05)	
Post-bronchodilator: Baseline (n=147,141,146)	2.094 (± 0.061)	2.11 (± 0.061)	2.153 (± 0.053)	
Pre-bronchodilator: Week 53 (n=125,130,122)	0.128 (± 0.032)	0.032 (± 0.026)	0.018 (± 0.035)	
Post-bronchodilator: Week 53 (n=125,126,120)	0.085 (± 0.029)	-0.009 (± 0.025)	-0.058 (± 0.027)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53

End point title	Mean Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53[3]

End point description:

Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal

volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: liters				
arithmetic mean (standard error)				
Pre-bronchodilator: Baseline (n=147,146,146)	2.809 (± 0.072)	2.827 (± 0.074)	2.83 (± 0.064)	
Post-bronchodilator: Baseline (n=147,141,146)	2.981 (± 0.075)	2.98 (± 0.076)	3.055 (± 0.067)	
Pre-bronchodilator: Week 53 (n=125,130,122)	0.117 (± 0.037)	0.003 (± 0.031)	0.007 (± 0.036)	
Post-bronchodilator: Week 53 (n=125,126,120)	0.06 (± 0.033)	-0.024 (± 0.029)	-0.057 (± 0.03)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 53

End point title	Mean Change From Baseline in Forced Vital Capacity (FVC) at Week 53[4]

End point description:

Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: liters				
arithmetic mean (standard error)				
Pre-bronchodilator: Baseline (n=147,146,146)	2.955 (± 0.075)	2.993 (± 0.079)	3.003 (± 0.069)	
Post-bronchodilator: Baseline (n=147,141,146)	3.133 (± 0.078)	3.125 (± 0.08)	3.225 (± 0.072)	
Pre-bronchodilator: Week 53 (n=125,130,122)	0.11 (± 0.042)	-0.018 (± 0.032)	-0.001 (± 0.039)	
Post-bronchodilator: Week 53 (n=125,126,120)	0.045 (± 0.034)	-0.03 (± 0.031)	-0.071 (± 0.032)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline in Ratio of Forced Expiratory Volume in 1 Second (FEV1)/Forced Vital Capacity (FVC) at Week 53

End point title	Mean Change From Baseline in Ratio of Forced Expiratory Volume in 1 Second (FEV1)/Forced Vital Capacity (FVC) at Week 53[5]

End point description:

Pre- and post-bronchodilator FEV1 and FVC at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Ratio of FEV1/FVC was analysed. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage of ratio				
arithmetic mean (standard error)				
Pre-bronchodilator: Baseline (n=147,146,146)	65.071 (± 1.013)	65.008 (± 1.009)	64.508 (± 0.986)	
Post-bronchodilator: Baseline (n=147,141,146)	66.831 (± 1.056)	67.883 (± 1.01)	67.152 (± 0.997)	

Pre-bronchodilator: Week 53 (n=125,130,122)	1.695 (± 0.517)	1.155 (± 0.527)	0.32 (± 0.685)	
Post-bronchodilator: Week 53 (n=125,126,120)	1.593 (± 0.563)	0.032 (± 0.484)	-0.512 (± 0.513)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline in Inspiratory Capacity (IC) at Week 53

End point title	Mean Change From Baseline in Inspiratory Capacity (IC) at Week 53[6]

End point description:

Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: liters				
arithmetic mean (standard error)				
Pre-bronchodilator: Baseline (n=140,138,143)	0.023 (± 0.001)	0.023 (± 0.001)	0.022 (± 0.001)	
Post-bronchodilator: Baseline (n=140,133,135)	0.024 (± 0.001)	0.024 (± 0.001)	0.024 (± 0.001)	
Pre-bronchodilator: Week 53 (n=108,109,103)	0 (± 0)	0.001 (± 0.001)	0.001 (± 0.001)	
Post-bronchodilator: Week 53 (n=108,109,104)	0.001 (± 0.001)	0 (± 0.001)	0 (± 0.001)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home

End point title	Mean Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home[7]

End point description:

Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: liters				
arithmetic mean (standard error)				
Day 1-7: Morning (n=151,149,149)	1.61 (± 0.05)	1.66 (± 0.05)	1.63 (± 0.05)	
Change at Day 365-371: Morning (n=124,119,114)	0.01 (± 0.04)	-0.07 (± 0.06)	-0.12 (± 0.06)	
Day 1-7: Evening (n=149,147,148)	1.68 (± 0.05)	1.65 (± 0.05)	1.61 (± 0.05)	
Change at Day 365-371: Evening (n=120,116,112)	-0.08 (± 0.05)	-0.12 (± 0.05)	-0.08 (± 0.05)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home

End point title	Mean Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home[8]

End point description:

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using any medication (if needed) for asthma. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: liters per minute				
arithmetic mean (standard error)				
Day 1-7: Morning (n=151,149,149)	271 (± 9.7)	281.2 (± 9.9)	273.7 (± 8.7)	
Change at Day 365-371: Morning (n=124,119,114)	-8 (± 7.9)	-24 (± 9.6)	-23.1 (± 8.8)	
Day 1-7: Evening (n=149,147,148)	287.6 (± 9.9)	283.8 (± 10)	276 (± 8.9)	
Change at Day 365-371: Evening (n=120,116,112)	-27 (± 8.2)	-36.5 (± 8.8)	-16.4 (± 8.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Mean Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 53

End point title	Change from Baseline in Mean Asthma Control Questionnaire (6-items) (ACQ-6) Score at Week 53[9]

End point description:

Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Results were reported for overall ACQ score. Data was summarized together for placebo arm groups. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: units on a scale				
arithmetic mean (standard error)				
Baseline (n=149,147,148)	2.59 (± 0.09)	2.54 (± 0.08)	2.52 (± 0.07)	
Change at Week 53 (n=118,115,112)	-1.02 (± 0.1)	-0.93 (± 0.11)	-0.82 (± 0.1)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Asthma Quality of Life Questionnaire Standardized Version (AQLQ[S]) Score at Week 53

End point title	Change from Baseline in Asthma Quality of Life Questionnaire Standardized Version (AQLQ[S]) Score at Week 53[10]

End point description:

AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: units on a scale				
arithmetic mean (standard error)				
Baseline: Overall (n=147,142,141)	3.98 (± 0.09)	4.08 (± 0.09)	4.05 (± 0.09)	
Week 53: Overall (n=107,109,101)	1.04 (± 0.1)	1 (± 0.12)	0.85 (± 0.1)	
Baseline: Symptoms (n=147,142,141)	4.03 (± 0.09)	4.13 (± 0.09)	4.1 (± 0.09)	
Week 53: Symptoms (n=107,109,101)	1.14 (± 0.12)	1.05 (± 0.13)	0.85 (± 0.11)	
Baseline: Activity limitation (n=147,142,141)	4.04 (± 0.09)	4.13 (± 0.09)	4.04 (± 0.08)	
Week 53: Activity limitation (n=107,109,101)	0.96 (± 0.1)	0.93 (± 0.12)	0.81 (± 0.1)	
Baseline: Emotional Function (n=147,142,141)	3.91 (± 0.12)	4.02 (± 0.11)	4.14 (± 0.12)	
Week 53: Emotional Function (n=107,109,101)	1.1 (± 0.12)	1.09 (± 0.15)	0.89 (± 0.12)	
Baseline: Environmental stimuli (n=147,142,141)	3.76 (± 0.12)	3.89 (± 0.12)	3.8 (± 0.11)	

Week 53: Environmental stimuli (n=107,109,101)	0.86 (± 0.14)	0.97 (± 0.14)	0.88 (± 0.13)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With European Quality of Life 5 Dimensions (EQ-5D) Scores at Week 53

End point title	Number of Participants With European Quality of Life 5 Dimensions (EQ-5D) Scores at Week 53[11]

End point description:

The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The health state valuation was the summary score of mobility, self-care, usual activities, pain/discomfort and anxiety/depression on a 3 category scale (no problem, moderate problem, severe problems). The minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study.

End point type	Secondary

End point timeframe:

Week 53

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: participants				
Mobility - No problem	118	106	107	
Mobility - Moderate problem	18	23	26	
Mobility - Severe Problem	0	1	1	
Mobility - Missing	14	21	17	
Self-care - No Problem	127	122	122	
Self-care - Moderate Problem	9	7	12	
Self-care - Severe Problem	0	1	0	
Self-care - Missing	14	21	17	
Usual activities - No Problem	106	100	89	
Usual activities - Moderate Problem	30	30	43	
Usual activities - Severe Problem	0	0	2	
Usual activities - Missing	14	21	17	
Pain/discomfort - No problem	100	77	84	
Pain/discomfort - Moderate problem	34	51	46	
Pain/discomfort - Severe problem	2	2	4	
Pain/discomfort - Missing	14	21	17	

Anxiety/depression - No problem	101	101	102	
Anxiety/depression - Moderate problem	34	29	29	
Anxiety/depression - Severe problem	1	0	3	
Anxiety/depression - Missing	14	21	17	

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Week 53

End point title	Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D) Visual Analog Scale (VAS) at Week 53[12]

End point description:

The utility-based EQ-5D questionnaire comprises of two parts and provides a generic measure of health for clinical and economic appraisal. The EQ-5D VAS was measured from 0 (worst imaginable health state) to 100 (best imaginable health state). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	136[13]	127[14]	130[15]	
Units: units on a scale				
arithmetic mean (standard error)	9.3 (± 1.9)	7.3 (± 1.8)	8.4 (± 1.6)	

Notes:

[13] - ITT population with evaluable participants for this endpoint for the specified time-point.

[14] - ITT population with evaluable participants for this endpoint for the specified time-point.

[15] - ITT population with evaluable participants for this endpoint for the specified time-point.

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Assessing Symptoms of Moderate-to-severe Asthma (ASMA) at Week 53

End point title	Change From Baseline in Assessing Symptoms of Moderate-to-severe Asthma (ASMA) at Week 53[16]

End point description:

There were 3 symptom questions in the ASMA diary: daytime frequency (question 1), daytime severity (question 2) and nighttime severity (question 6). All symptom questions were scored from 0 to 4 averaged, where a higher score indicated greater frequency or severity. Asthma symptom scores were

averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline (Day -7 – Day -1) and Week 53 (Day 365 – Day 371)

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: units on a scale				
arithmetic mean (standard deviation)				
Day -7 - Day -1 (Baseline) (n=151,147,145)	1.49 (± 0.77)	1.56 (± 0.69)	1.6 (± 0.71)	
Change at Day 365 - Day 371 (n=113,108,108)	-0.42 (± 0.73)	-0.49 (± 0.78)	-0.43 (± 0.75)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Rescue Medication use at Week 53

End point title	Change From Baseline in Rescue Medication use at Week 53[17]

End point description:

Rescue medication use was collected from 3 questions: daytime use in response to symptoms (question 3), daytime prophylactic use (question 4) and nighttime use (question 7). Rescue medication use questions were first assessed using a dichotomous response option (YES/NO). If the participants reported YES, there was a subsequent question about the number of times rescue medication was used (questions 3a, 4a, and 7a). Daily average scores were summarized each week for all participants with at least 4 non-missing records each week. Days with no reported rescue medication use were represented as 0 and included in the calculation with participants who reported yes and completed questions 3a, 4a and 7a. The baseline scores were calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline (Day -7 – Day -1) and Week 53 (Day 365 – Day 371)

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[18]	151[19]	151[20]	
Units: use per day				
arithmetic mean (standard deviation)				
Day -7 - Day -1 (Baseline) (n=151,147,145)	2.77 (± 3.78)	2.38 (± 2.58)	2.56 (± 2.73)	
Change at Day 365 - Day 371 (n=113,108,108)	-0.77 (± 2.59)	-1.02 (± 2.3)	-0.86 (± 2.2)	

Notes:

[18] - ITT population

[19] - ITT population

[20] - ITT population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)

End point title	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (TESAEs)[21]

End point description:

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to Week 75 that were absent before treatment or that worsened relative to pre-treatment state. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The safety population included all participants who received any investigational product and had safety data available for analysis.

End point type	Secondary

End point timeframe:

Baseline and Week 75

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: participants				
TEAEs	134	128	129	
TESAEs	18	25	21	

Statistical analyses

No statistical analyses for this end point

Secondary: Observed Serum Tralokinumab Concentration at Week 53

End point title	Observed Serum Tralokinumab Concentration at Week 53[22]

End point description:

Tralokinumab concentrations that were below limit of quantification (LOQ) of the pharmacokinetic (PK) assay (LOQ = 0.500 microgram per milliliter [mcg/mL]) were replaced by LOQ/2 = 0.250 mcg/mL; results were reported to 3 significant figures level of precision. Observed serum tralokinumab concentration at Week 53 was reported. The PK population included all participants who received at least one dose of tralokinumab and had at least one quantifiable PK observation. Here "N" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Week 53

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	128		
Units: microgram per milliliter				
arithmetic mean (standard deviation)	71.3 (± 34.2)	25.8 (± 11.8)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants with Anti-Drug Antibodies (ADA) to Tralokinumab

End point title	Percentage of Participants with Anti-Drug Antibodies (ADA) to Tralokinumab[23]

End point description:

Immunogenicity assessment included determination of anti-drug (tralokinumab) antibodies in serum samples. ADA positive was defined as a titer greater than or equal to (>=13) at any point in the study. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The PK population included all participants who received at least one dose of tralokinumab and had at least one quantifiable PK observation. Here "N" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Baseline and Week 75

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage of participants				
number (not applicable)				
Baseline (Week 1) (n=151,150,151)	0.67	1.3	1.3	
Week 75 (n=151,150,150)	0	4	3.3	

Statistical analyses

No statistical analyses for this end point

Secondary: Severe Annual Asthma Exacerbation Rate (AER)

End point title	Severe Annual Asthma Exacerbation Rate (AER)[24]

End point description:

Severe annualized AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed or administered by the investigator; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. An asthma exacerbation event was considered resolved 7 days after the last dose of oral corticosteroids is administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[25]	151[26]	151[27]	
Units: AER events/person-year				
number (confidence interval 95%)	0.11 (0.06 to 0.17)	0.1 (0.05 to 0.17)	0.17 (0.1 to 0.25)	

Notes:

[25] - ITT population

[26] - ITT population

[27] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.293
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.26
upper limit	1.51

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status (atopic/non-atopic), chronic OCS use (presence vs absence) and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.27
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.27
upper limit	1.44

Secondary: Time to First Exacerbation Through Week 53

End point title	Time to First Exacerbation Through Week 53[28]

End point description:

Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. In the below table, '99999' indicates the median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events. The ITT population included all participants who were randomized into the study.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.257
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	1.16

Statistical analysis title	Statistical analysis 2
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.225
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.15

Secondary: Time to First Severe Exacerbation Through Week 53

End point title	Time to First Severe Exacerbation Through Week 53[29]

End point description:

Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. In the below table, '99999' indicates the median and lower and upper limits of the 95% Confidence Interval were incalculable due to an insufficient number of events. The ITT population included all participants who were randomized into the study.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[29] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: days				
median (confidence interval 95%)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	

Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.538
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	1.68

Statistical analysis title	Statistical analysis 2
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.561
Method	Regression, Cox
Parameter estimate	Hazard ratio (HR)
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	1.71

Secondary: Annual Asthma Exacerbation Rate (AER) by Baseline Serum Periostin

End point title	Annual Asthma Exacerbation Rate (AER) by Baseline Serum Periostin[30]

End point description:

Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline serum periostin >= or <median, >= or < 25th percentile and >= or < 75th percentile. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[31]	151[32]	151[33]	
Units: AER events/person-year				
number (confidence interval 95%)				
>= median (n=67,81,79)	0.85 (0.65 to 1.08)	1.27 (1.03 to 1.55)	1.13 (0.88 to 1.43)	
< median (n=84,69,71)	0.98 (0.76 to 1.25)	0.63 (0.45 to 0.85)	0.73 (0.55 to 0.95)	
>= 25th Percentile (n=105,115,119)	0.84 (0.67 to 1.03)	1.05 (0.87 to 1.25)	0.94 (0.75 to 1.15)	
< 25th Percentile (n=46,35,31)	1.14 (0.81 to 1.56)	0.65 (0.38 to 1.05)	0.83 (0.58 to 1.16)	
>= 75th Percentile (n=32,43,39)	0.91 (0.65 to 1.25)	2.03 (1.6 to 2.55)	1.13 (0.76 to 1.6)	

< 75th Percentile (n=119,107,111)	0.91 (0.73 to 1.11)	0.6 (0.46 to 0.77)	0.85 (0.69 to 1.04)	

Notes:

[31] - ITT population

[32] - ITT population

[33] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description: Baseline serum periostin >= median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.19
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.73
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.46
upper limit	1.17

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline serum periostin >= median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.856
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.61

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline serum periostin < median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.602
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	1.81

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Baseline serum periostin < median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.703
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.55
upper limit	1.5

Statistical analysis title	Statistical analysis 5
Statistical analysis description: Baseline serum periostin >= 25th Percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.455
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	1.28

Statistical analysis title	Statistical analysis 6
Statistical analysis description: Baseline serum periostin >= 25th Percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.929
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.57

Statistical analysis title	Statistical analysis 7
Statistical analysis description: Baseline serum periostin < 25th Percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.507
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.63
upper limit	2.51

Statistical analysis title	Statistical analysis 8
Statistical analysis description: Baseline serum periostin < 25th Percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.805
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.44
upper limit	1.89

Statistical analysis title	Statistical analysis 9
Statistical analysis description: Baseline serum periostin >= 75th Percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.716
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.44
upper limit	1.75

Statistical analysis title	Statistical analysis 10
Statistical analysis description: Baseline serum periostin >= 75th Percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.328
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.51
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	3.43

Statistical analysis title	Statistical analysis 11
Statistical analysis description: Baseline serum periostin < 75th Percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.804
Method	Poission regression
Parameter estimate	Rate Ratio
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	1.41

Statistical analysis title	Statistical analysis 12
Statistical analysis description: Baseline serum periostin < 75th Percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.088
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.47
upper limit	1.05

Secondary: Annual Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status

End point title	Annual Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status[34]

End point description:

Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Th2 status. Th2-high included those participants who had immunoglobulin E (IgE) >100 international unit per milliliter (IU/mL) and blood eosinophils >= 0.14

* 10 power 9 per Liter. Th2 low would include those participants who do not meet Th2 high status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[35]	151[36]	151[37]	
Units: AER events/person-year				
number (confidence interval 95%)				
Th2 high (n=70,74,67)	0.94 (0.73 to 1.2)	1.09 (0.85 to 1.39)	0.96 (0.74 to 1.23)	
Th2 Low (n=73,61,72)	0.88 (0.66 to 1.16)	0.85 (0.64 to 1.11)	0.9 (0.69 to 1.16)	

Notes:

[35] - ITT population

[36] - ITT population

[37] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	
Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.365
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.29

Statistical analysis title	Statistical analysis 2
Statistical analysis description:	
Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.922
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.68

Statistical analysis title	Statistical analysis 3
Statistical analysis description:	
Th2 Low	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.685
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	1.84

Statistical analysis title	Statistical analysis 4
Statistical analysis description:	
Th2 Low	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.813
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.7

Secondary: Annual Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count

End point title	Annual Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count[38]

End point description:

Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroups baseline peripheral blood eosinophil counts. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[39]	151[40]	151[41]	
Units: AER events/person-year				
number (confidence interval 95%)				
>= 150 cells/mcgL (n=95,104,92)	0.84 (0.66 to 1.04)	0.96 (0.77 to 1.19)	0.95 (0.76 to 1.18)	
< 150 cells/mcgL (n=48,38,52)	1.09 (0.78 to 1.48)	0.95 (0.69 to 1.27)	0.9 (0.64 to 1.22)	
>= 300 cells/mcgL (n=54,60,50)	1.01 (0.76 to 1.31)	1.56 (1.23 to 1.97)	1 (0.74 to 1.32)	
< 300 cells/mcgL (n=89,82,94)	0.83 (0.64 to 1.06)	0.63 (0.47 to 0.82)	0.89 (0.7 to 1.12)	

Notes:

[39] - ITT population

[40] - ITT population

[41] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Baseline eosinophil count >=150 cells/mcgL

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.335
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.22

Statistical analysis title	Statistical analysis 2
Statistical analysis description:	
Baseline eosinophil count >=150 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.586
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.54
upper limit	1.41

Statistical analysis title	Statistical Analysis 3
Statistical analysis description:	
Baseline eosinophil count <150 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.331
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.36
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	2.52

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Baseline eosinophil count <150 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.311
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	2.71

Statistical analysis title	statistical analysis 5
Statistical analysis description: Baseline eosinophil count >=300 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.414
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	1.35

Statistical analysis title	statistical analysis 6
Statistical analysis description: Baseline eosinophil count >=300 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.463
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.68
upper limit	2.36

Statistical analysis title	Statistical analysis 7
Statistical analysis description:	
Baseline eosinophil count <300 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.793
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.67
upper limit	1.68

Statistical analysis title	Statistical analysis 8
Statistical analysis description:	
Baseline eosinophil count <300 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.264
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.22

Secondary: Annual Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility

End point title	Annual Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility[42]

End point description:

Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup baseline FEV1 reversibility >=12% and <12%. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[43]	151[44]	151[45]	
Units: AER events/person-year				
number (confidence interval 95%)				
Reversibility >=12% (n=57,43,49)	0.68 (0.45 to 0.99)	1.08 (0.8 to 1.42)	0.88 (0.65 to 1.18)	
Reversibility <12% (n=91,101,97)	0.99 (0.8 to 1.21)	0.9 (0.71 to 1.12)	0.93 (0.73 to 1.16)	

Notes:

[43] - ITT population

[44] - ITT population

[45] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Baseline FEV1 reversibility >=12%

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.245
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.66

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.33
upper limit	1.32

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline FEV1 reversibility >=12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.438
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.76
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.37
upper limit	1.54

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline FEV1 reversibility <12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.947
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.57

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Baseline FEV1 reversibility <12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.916
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	1.59

Secondary: Annual Asthma Exacerbation Rate (AER) by Baseline FEV1% Predicted

End point title	Annual Asthma Exacerbation Rate (AER) by Baseline FEV1% Predicted[46]

End point description:

Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER was evaluated by subgroup baseline FEV1% predicaed. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[47]	151[48]	151[49]	
Units: AER events/person-year				
number (confidence interval 95%)				
FEV1% Predicted <=60% (n=49,45,56)	0.95 (0.68 to 1.29)	1.67 (1.34 to 2.07)	1.05 (0.77 to 1.4)	
FEV1% Predicted <=80% (n=119,109,105)	0.88 (0.71 to 1.08)	1.13 (0.93 to 1.36)	0.93 (0.76 to 1.13)	

Notes:

[47] - ITT population

[48] - ITT population

[49] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description: Baseline FEV1% predicted <=60%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.723
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.52
upper limit	1.56

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline FEV1% predicted <=60%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.852
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.06
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.86

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline FEV1% predicted <=80%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.409
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.86

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.6
upper limit	1.23

Statistical analysis title	Statistical analysis 4
Statistical analysis description:	
Baseline FEV1% predicted <=80%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.744
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.72
upper limit	1.58

Secondary: Annual Asthma Exacerbation Rate (AER) by Asthma Exacerbations in the Past Year

End point title	Annual Asthma Exacerbation Rate (AER) by Asthma Exacerbations in the Past Year[50]

End point description:

Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup as asthma exacerbations in the past year. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure at specified time points.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[51]	151[52]	151[53]	
Units: AER events/person-year				
number (confidence interval 95%)				
2 asthma exacerbations (n=97,96,95)	0.61 (0.45 to 0.79)	0.45 (0.32 to 0.61)	0.62 (0.47 to 0.81)	
> 2 but < 6 asthma exacerbations (n=54,54,56)	1.42 (1.12 to 1.78)	1.88 (1.52 to 2.3)	1.44 (1.12 to 1.82)	

Notes:

[51] - ITT population

[52] - ITT population

[53] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description: 2 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.802
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.94
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.58
upper limit	1.52

Statistical analysis title	Statistical analysis 2
Statistical analysis description: 2 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.05
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.6

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.36
upper limit	1

Statistical analysis title	Statistical analysis 3
Statistical analysis description:	
> 2 but < 6 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.792
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.93
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.56
upper limit	1.56

Statistical analysis title	Statistical analysis 4
Statistical analysis description:	
> 2 but < 6 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.231
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.39
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.81
upper limit	2.38

Secondary: Severe Asthma Exacerbation Rate (AER) by Baseline Serum Periostin

End point title	Severe Asthma Exacerbation Rate (AER) by Baseline Serum Periostin[54]

End point description:

Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER evaluated by subgroup baseline serum periostin. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[55]	151[56]	151[57]	
Units: AER events/person-year				
number (confidence interval 95%)				
>= median (n=67,81,79)	0.08 (0.03 to 0.17)	0.12 (0.06 to 0.23)	0.25 (0.14 to 0.4)	
< median (n=84,69,71)	0.14 (0.06 to 0.26)	0.08 (0.03 to 0.18)	0.1 (0.04 to 0.2)	

Notes:

[55] - ITT population

[56] - ITT population

[57] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Baseline Serum Periostin >=Median

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.046
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.06
upper limit	0.98

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline Serum Periostin >=Median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.197
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.15
upper limit	1.48

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline Serum Periostin < Median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.708
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	2.79

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Baseline Serum Periostin < Median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.594
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.48
upper limit	3.57

Secondary: Severe Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility

End point title	Severe Asthma Exacerbation Rate (AER) by Baseline FEV1 Reversibility[58]

End point description:

Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS administered (10 days after an injectable corticosteroid). Courses of corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup FEV1 reversibility. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[59]	151[60]	151[61]	
Units: AER events/person-year				
number (confidence interval 95%)				
Reversibility >=12% (n=57,43,49)	0.13 (0.04 to 0.29)	0.13 (0.05 to 0.28)	0.11 (0.04 to 0.25)	
Reversibility <12% (n=91,101,97)	0.1 (0.05 to 0.19)	0.09 (0.04 to 0.18)	0.2 (0.12 to 0.32)	

Notes:

[59] - ITT population

[60] - ITT population

[61] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description: Baseline FEV1 reversibility >=12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.975
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.14
upper limit	7.67

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline FEV1 reversibility >=12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.473
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	1.66
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.41
upper limit	6.67

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline FEV1 reversibility <12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.099
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.49

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.21
upper limit	1.14

Statistical analysis title	Statistical analysis 4
Statistical analysis description:	
Baseline FEV1 reversibility <12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.148
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.13
upper limit	1.36

Secondary: Severe Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status

End point title	Severe Asthma Exacerbation Rate (AER) by T-helper-2 (Th2) Status[62]

End point description:

Severe AER was assessed based on AER data up to Week 53. An asthma exacerbation is a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 days. It was considered resolved 7 days after last dose of OCS (10 days after injectable corticosteroid). Corticosteroids initiated after this time period were considered separate new asthma exacerbation. Severe AER was evaluated by subgroup Th2 status. Th2-high include who had IgE >100 IU/mL and blood eosinophils >=0.14*10^9/L. Th2 low would include who do not meet Th2 high status. Data were summarized together for ‘Placebo, Q2W’ and ‘Placebo, Q2/4W’ arms. Here "n" signifies evaluable participants for this measure.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[62] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[63]	151[64]	151[65]	
Units: AER events/person-year				
number (confidence interval 95%)				
Th2 high (n=70,74,67)	0.12 (0.05 to 0.23)	0.06 (0.02 to 0.16)	0.12 (0.05 to 0.24)	
Th2 Low (n=73,61,72)	0.05 (0.01 to 0.15)	0.12 (0.05 to 0.24)	0.21 (0.11 to 0.35)	

Notes:

[63] - ITT population

[64] - ITT population

[65] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description: Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.698
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.31
upper limit	2.19

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.299
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.55

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.18
upper limit	1.7

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Th2 Low	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.105
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.05
upper limit	1.34

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Th2 Low	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.576
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.2
upper limit	2.47

Secondary: Severe Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count

End point title	Severe Asthma Exacerbation Rate (AER) by Baseline Peripheral Blood Eosinophil Count[66]

End point description:

Severe AER was assessed based on AER data up to Week 53. Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS (10 days after an injectable corticosteroid). Corticosteroids initiated after this time period were considered a separate new asthma exacerbation. Severe AER was evaluated by subgroup baseline peripheral blood eosinophil count. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. Here "n" signifies evaluable participants for this measure.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[66] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150[67]	151[68]	151[69]	
Units: AER events/person-year				
number (confidence interval 95%)				
>= 300 cells/mcgL (n=54,60,50)	0.16 (0.07 to 0.31)	0.15 (0.06 to 0.31)	0.22 (0.11 to 0.4)	
< 300 cells/mcgL (n=89,82,94)	0.08 (0.03 to 0.16)	0.08 (0.03 to 0.17)	0.13 (0.07 to 0.24)	

Notes:

[67] - ITT population

[68] - ITT population

[69] - ITT population

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

Baseline eosinophil count >=300 cells/mcgL

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.133
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	1.25

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline eosinophil count >=300 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.241
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.13
upper limit	1.67

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline eosinophil count <300 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.51
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.12
upper limit	2.84

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Baseline eosinophil count <300 cells/mcgL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.661
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.74
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.19
upper limit	2.85

Secondary: Percent Change from Baseline in Prebronchodilator FEV1 at Week 53 in Subgroups

End point title	Percent Change from Baseline in Prebronchodilator FEV1 at Week 53 in Subgroups[70]

End point description:

Prebronchodilator FEV1 was evaluated by subgroups. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[70] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: Percent change				
arithmetic mean (standard error)				
Baseline SP >=median (n=54,71,65)	10.48 (± 3.01)	4.36 (± 2.25)	4.17 (± 2.75)	
Baseline SP <median (n=71,59,56)	7.46 (± 3)	1.3 (± 2.12)	1.23 (± 2.82)	
Baseline SP >=25th Percentile (n=88,102,100)	10.4 (± 2.43)	2.31 (± 1.66)	4.1 (± 2.29)	
Baseline SP <25th Percentile (n=37,28,21)	4.4 (± 4.39)	5.99 (± 4.22)	-1.29 (± 3.92)	
Baseline SP >=75th Percentile (n=25,40,32)	11.05 (± 4.67)	2.97 (± 3.33)	2.32 (± 4.07)	
Baseline SP <75th Percentile (n=100,90,89)	8.25 (± 2.29)	2.94 (± 1.75)	2.55 (± 2.28)	
Th2 high (n=63,62,57)	11.62 (± 3.23)	4.52 (± 2.39)	2.1 (± 2.62)	
Th2 low (n=57,55,55)	3.87 (± 2.5)	0.13 (± 1.72)	1.9 (± 3.09)	
Baseline PBEC >=150 cells/mcgL (n=81,89,75)	10.97 (± 2.71)	4.67 (± 2.17)	1.98 (± 2.32)	

Baseline PBEC <150 cells/mcgL (n=39,34,40)	5.75 (± 3.75)	-0.4 (± 2)	2.05 (± 3.89)	
Baseline PBEC >=300 cells/mcgL (n=45,51,39)	14.04 (± 3.88)	4.65 (± 2.9)	0.59 (± 2.88)	
Baseline PBEC <300 cells/mcgL (n=75,72,76)	6.33 (± 2.57)	2.01 (± 1.89)	2.85 (± 2.71)	
Baseline FEV1 reversibility >=12% (n=49,36,41)	22.78 (± 5.2)	11.8 (± 3.48)	11.02 (± 3.85)	
Baseline FEV1 reversibility <12% (n=76,92,80)	3.98 (± 1.97)	-1.66 (± 1.28)	-2.99 (± 1.9)	
2 asthma exacerbations (n=84,81,82)	8.99 (± 2.41)	3.57 (± 2.04)	0.76 (± 2.16)	
> 2 but < 6 asthma exacerbations (n=41,49,40)	9.32 (± 4.05)	1.63 (± 2.17)	6.08 (± 4.12)	
Chronic OCS use (n=20,21,16)	6.96 (± 6.56)	-0.48 (± 5.31)	3.44 (± 5.82)	
Without chronic OCS use (n=105,109,106)	9.52 (± 2.22)	3.45 (± 1.59)	2.32 (± 2.1)	

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description: Baseline serum periostin >= median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.057
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	6.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.21
upper limit	13.79

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline serum periostin >= median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.874
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.57

Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.54
upper limit	7.68

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline serum periostin < median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.028
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	7.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.8
upper limit	13.95

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Baseline serum periostin < median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.745
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	1.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.48
upper limit	7.66

Statistical analysis title	Statistical analysis 5
Statistical analysis description: Baseline serum periostin >= 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.011
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	7.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.66
upper limit	12.58

Statistical analysis title	Statistical analysis 6
Statistical analysis description: Baseline serum periostin >= 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.863
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.48
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.93
upper limit	4.97

Statistical analysis title	Statistical analysis 7
Statistical analysis description: Baseline serum periostin < 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.221
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	6.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.8
upper limit	16.27

Statistical analysis title	Statistical analysis 8
Statistical analysis description: Baseline serum periostin < 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.108
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	8.58
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.91
upper limit	19.07

Statistical analysis title	Statistical analysis 9
Statistical analysis description: Baseline serum periostin >= 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.09
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	9.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.57
upper limit	21.35

Statistical analysis title	Statistical analysis 10
Statistical analysis description: Baseline serum periostin >= 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.908
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.19
upper limit	12.59

Statistical analysis title	Statistical analysis 11
Statistical analysis description:	
Baseline serum periostin < 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.013
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	6.52
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.41
upper limit	11.64

Statistical analysis title	Statistical analysis 12
Statistical analysis description:	
Baseline serum periostin < 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.635
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	1.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.84
upper limit	6.29

Statistical analysis title	Statistical analysis 13
Statistical analysis description: Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.014
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	8.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.84
upper limit	15.94

Statistical analysis title	Statistical analysis 14
Statistical analysis description: Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.28
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	3.91
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.19
upper limit	11.02

Statistical analysis title	Statistical analysis 15
Statistical analysis description: Th2 low	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.292
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	3.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.78
upper limit	9.22

Statistical analysis title	Statistical analysis 16
Statistical analysis description:	
Th2 low	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.691
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-1.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	-6.99
upper limit	4.64

Statistical analysis title	Statistical analysis 17
Statistical analysis description:	
Baseline peripheral blood eosinophil count >= 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.004
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	8.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.85
upper limit	14.81

Statistical analysis title	Statistical analysis 18
Statistical analysis description: Baseline peripheral blood eosinophil count >= 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.177
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	4.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.92
upper limit	10.43

Statistical analysis title	Statistical analysis 19
Statistical analysis description: Baseline peripheral blood eosinophil count < 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.159
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	6.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.39
upper limit	14.5

Statistical analysis title	Statistical analysis 20
Statistical analysis description: Baseline peripheral blood eosinophil count < 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.857
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	-8.63
upper limit	7.18

Statistical analysis title	Statistical analysis 21
Statistical analysis description: Baseline peripheral blood eosinophil count >= 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.002
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	13.75
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.28
upper limit	22.22

Statistical analysis title	Statistical analysis 22
Statistical analysis description: Baseline peripheral blood eosinophil count >= 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.243
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	5.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.56
upper limit	14.02

Statistical analysis title	Statistical analysis 23
Statistical analysis description: Baseline peripheral blood eosinophil count < 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.144
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	4.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	10.24

Statistical analysis title	Statistical analysis 24
Statistical analysis description: Baseline peripheral blood eosinophil count < 300 cells/µ	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.804
Method	Baseline peripheral blood eosinophil cou
Parameter estimate	Difference of LS-mean
Point estimate	0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.01
upper limit	6.46

Statistical analysis title	Statistical analysis 25
Statistical analysis description: Baseline FEV1 reversibility >= 12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.029
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	11.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.15
upper limit	21.23

Statistical analysis title	Statistical analysis 26
Statistical analysis description: Baseline FEV1 reversibility >= 12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.887
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.72
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.19
upper limit	10.62

Statistical analysis title	Statistical analysis 27
Statistical analysis description: Baseline FEV1 reversibility < 12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.002
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	7.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.76
upper limit	12.59

Statistical analysis title	Statistical analysis 28
Statistical analysis description: Baseline FEV1 reversibility < 12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.268
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	2.79
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.15
upper limit	7.74

Statistical analysis title	Statistical analysis 29
Statistical analysis description: 2 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.003
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	7.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.64
upper limit	13.01

Statistical analysis title	Statistical analysis 30
Statistical analysis description: 2 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.361
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	2.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.78
upper limit	7.62

Statistical analysis title	Statistical analysis 31
Statistical analysis description: > 2 but < 6 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.185
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	6.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.06
upper limit	15.75

Statistical analysis title	Statistical analysis 32
Statistical analysis description: > 2 but < 6 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.986
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.5
upper limit	9.34

Statistical analysis title	Statistical analysis 33
Statistical analysis description: Chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.912
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	-14.7
upper limit	16.44

Statistical analysis title	Statistical analysis 34
Statistical analysis description: Chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.86
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-1.46
Confidence interval	
level	95 %
sides	2-sided
lower limit	-17.76
upper limit	14.84

Statistical analysis title	Statistical analysis 35
Statistical analysis description: Without chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.002
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	7.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.76
upper limit	12.36

Statistical analysis title	Statistical analysis 36
Statistical analysis description:	
Without chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.601
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	1.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.51
upper limit	6.06

Secondary: Change from Baseline in Mean ACQ-6 Scores at Week 53 in Subgroups

End point title	Change from Baseline in Mean ACQ-6 Scores at Week 53 in Subgroups[71]

End point description:

Asthma Control Questionnaire (ACQ) is a participant-reported questionnaire to assess the asthma control with 6 items assessing night-time waking, symptoms on waking, activity limitation, shortness of breath, wheeze, and rescue short-acting beta agonist use. Each item was rated on a 7-point Likert scale ranging from 0 (no impairment) to 6 (maximum impairment). Overall ACQ score was the mean of the 6 item scores with a score range of 0 (well controlled) to 6 (extremely poor controlled). Data collected on Day 1 prior to dosing was considered as baseline. Results were reported for overall ACQ score. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[71] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: units on a scale				
arithmetic mean (standard error)				
Baseline SP >= Median (n= 51, 65, 60)	-1.18 (± 0.13)	-0.85 (± 0.14)	-0.88 (± 0.15)	
Baseline SP < Median (n= 67, 50, 52)	-0.81 (± 0.15)	-1.03 (± 0.17)	-0.77 (± 0.14)	
Baseline SP >= 25th Percentile (n= 82, 92, 91)	-1.04 (± 0.11)	-0.93 (± 0.13)	-0.86 (± 0.12)	
Baseline SP <25th Percentile (n= 36, 23, 21)	-0.95 (± 0.24)	-0.92 (± 0.24)	-0.73 (± 0.19)	
Baseline SP >=75th Percentile (n= 25, 34, 27)	-1.25 (± 0.18)	-1.01 (± 0.23)	-0.75 (± 0.14)	
Baseline SP <75th Percentile (n= 93, 81, 85)	-0.92 (± 0.12)	-0.91 (± 0.13)	-0.84 (± 0.12)	
Th2 High (n= 59, 56, 55)	-1.1 (± 0.15)	-1.02 (± 0.15)	-0.95 (± 0.13)	
Th2 Low (n= 55, 47, 50)	-0.94 (± 0.14)	-0.87 (± 0.17)	-0.7 (± 0.16)	
Baseline EC >= 150 Cells/UL (n= 77, 78, 70)	-1.07 (± 0.13)	-0.94 (± 0.13)	-0.84 (± 0.13)	
Baseline EC < 150 Cells/UL (n= 37, 31, 37)	-0.92 (± 0.16)	-1.02 (± 0.21)	-0.81 (± 0.18)	
Baseline EC >= 300 Cells/UL (n= 43, 44, 37)	-1.24 (± 0.16)	-0.91 (± 0.17)	-0.77 (± 0.15)	
Baseline EC < 300 Cells/UL (n= 71, 65, 70)	-0.88 (± 0.12)	-1 (± 0.15)	-0.86 (± 0.14)	
Baseline FEV1 Reversibility >=12% (n= 43, 33, 35)	-0.9 (± 0.18)	-0.76 (± 0.2)	-0.47 (± 0.19)	
Baseline FEV1 Reversibility <12% (n= 73, 78, 75)	-1.12 (± 0.12)	-1.02 (± 0.13)	-1.03 (± 0.11)	
2 Asthma Exacerbations (n= 79, 72, 75)	-0.94 (± 0.13)	-0.95 (± 0.14)	-0.77 (± 0.13)	
>2 Asthma Exacerbations (n= 39, 43, 37)	-1.15 (± 0.15)	-0.9 (± 0.19)	-0.93 (± 0.17)	
With Chronic OCS Use (n= 20, 17, 18)	-0.89 (± 0.28)	-0.16 (± 0.23)	-0.39 (± 0.25)	
Without Chronic OCS Use (n= 98, 98, 94)	-1.04 (± 0.11)	-1.08 (± 0.12)	-0.91 (± 0.11)	

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description:	
Baseline serum periostin >= median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.145
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.57
upper limit	0.08

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline serum periostin >= median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.759
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.28
upper limit	0.38

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline serum periostin < median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.936
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.38
upper limit	0.35

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Baseline serum periostin < median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.127
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.64
upper limit	0.08

Statistical analysis title	Statistical analysis 5
Statistical analysis description: Baseline serum periostin>= 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.343
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.41
upper limit	0.14

Statistical analysis title	Statistical analysis 6
Statistical analysis description: Baseline serum periostin>= 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.928
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.29
upper limit	0.27

Statistical analysis title	Statistical analysis 7
Statistical analysis description:	
Baseline serum periostin < 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.374
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.74
upper limit	0.28

Statistical analysis title	Statistical analysis 8
Statistical analysis description:	
Baseline serum periostin < 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.259
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.81
upper limit	0.22

Statistical analysis title	Statistical analysis 9
Statistical analysis description: Baseline serum periostin >= 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.127
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.84
upper limit	0.11

Statistical analysis title	Statistical analysis 10
Statistical analysis description: Baseline serum periostin >= 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.775
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.56
upper limit	0.42

Statistical analysis title	Statistical analysis 11
Statistical analysis description: Baseline serum periostin < 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.512
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.38
upper limit	0.19

Statistical analysis title	Statistical analysis 12
Statistical analysis description: Baseline serum periostin < 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.404
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.16

Statistical analysis title	Statistical analysis 13
Statistical analysis description: Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.181
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.59
upper limit	0.11

Statistical analysis title	Statistical analysis 14
Statistical analysis description: Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.161
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	0.1

Statistical analysis title	Statistical analysis 15
Statistical analysis description: Th2 low	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.54
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.47
upper limit	0.25

Statistical analysis title	Statistical analysis 16
Statistical analysis description: Th2 low	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.674
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.42
upper limit	0.27

Statistical analysis title	Statistical analysis 17
Statistical analysis description: Baseline peripheral blood eosinophil count >= 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.154
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.52
upper limit	0.08

Statistical analysis title	Statistical analysis 18
Statistical analysis description: Baseline peripheral blood eosinophil count >= 150 cells/µ	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.271
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.48
upper limit	0.13

Statistical analysis title	Statistical analysis 19
Statistical analysis description: Baseline peripheral blood eosinophil count < 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.725
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.08
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.51
upper limit	0.36

Statistical analysis title	Statistical analysis 20
Statistical analysis description: Baseline peripheral blood eosinophil count < 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.559
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.53
upper limit	0.28

Statistical analysis title	Statistical analysis 21
Statistical analysis description: Baseline peripheral blood eosinophil count >= 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.019
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.47
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.87
upper limit	-0.08

Statistical analysis title	Statistical analysis 22
Statistical analysis description:	
Baseline peripheral blood eosinophil count >= 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.348
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.61
upper limit	0.21

Statistical analysis title	Statistical analysis 23
Statistical analysis description:	
Baseline peripheral blood eosinophil count < 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.855
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.03
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.35
upper limit	0.29

Statistical analysis title	Statistical analysis 24
Statistical analysis description: Baseline peripheral blood eosinophil count < 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.203
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	0.11

Statistical analysis title	Statistical analysis 25
Statistical analysis description: Baseline FEV1 reversibility >= 12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.055
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.89
upper limit	0.01

Statistical analysis title	Statistical analysis 26
Statistical analysis description: Baseline FEV1 reversibility >= 12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.104
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.82
upper limit	0.08

Statistical analysis title	Statistical analysis 27
Statistical analysis description: Baseline FEV1 reversibility < 12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.652
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.37
upper limit	0.23

Statistical analysis title	Statistical analysis 28
Statistical analysis description: Baseline FEV1 reversibility < 12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.905
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.28
upper limit	0.32

Statistical analysis title	Statistical analysis 29
Statistical analysis description: 2 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.198
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.49
upper limit	0.1

Statistical analysis title	Statistical analysis 30
Statistical analysis description: 2 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.226
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.47
upper limit	0.11

Statistical analysis title	Statistical analysis 31
Statistical analysis description: > 2 but < 6 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.513
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.56
upper limit	0.28

Statistical analysis title	Statistical analysis 32
Statistical analysis description: > 2 but < 6 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.974
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	0.42

Statistical analysis title	Statistical analysis 33
Statistical analysis description: Chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.226
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.97
upper limit	0.23

Statistical analysis title	Statistical analysis 34
Statistical analysis description: Chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.613
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.44
upper limit	0.75

Statistical analysis title	Statistical analysis 35
Statistical analysis description: Without chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.198
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.43
upper limit	0.09

Statistical analysis title	Statistical analysis 36
Statistical analysis description: Without chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.165
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.45
upper limit	0.08

Secondary: Change from Baseline in Total AQLQ(S) Scores at Week 53 in Subgroups

End point title	Change from Baseline in Total AQLQ(S) Scores at Week 53 in Subgroups[72]

End point description:

AQLQ: a 32-item questionnaire evaluating quality of life of participants with asthma including 4 domains (symptoms, activity limitations, emotional function, and environmental stimuli). Participants were asked to recall their experiences during the previous 2 weeks and to score each of the 32 questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score was calculated as the mean response to all questions. The 4 domain scores were the means of the responses to the questions in each of the domains. Overall AQLQ score and 4 domain scores ranged from 7 (no impairment) to 1 (severe impairment). Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[72] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: units on a scale				
arithmetic mean (standard error)				
Baseline SP >=Median (n= 46, 63, 56)	1.1 (± 0.14)	0.95 (± 0.17)	0.89 (± 0.15)	
Baseline SP <Median (n= 61, 46, 45)	0.95 (± 0.15)	1.07 (± 0.17)	0.82 (± 0.14)	
Baseline SP >=25th Percentile (n= 73, 88, 82)	1.08 (± 0.11)	0.98 (± 0.14)	0.87 (± 0.12)	
Baseline SP <25th Percentile (n= 34, 21, 19)	0.84 (± 0.24)	1.09 (± 0.24)	0.81 (± 0.19)	
Baseline SP >=75th Percentile (n= 23, 33, 24)	1.2 (± 0.19)	1.13 (± 0.28)	0.76 (± 0.17)	
Baseline SP <75th Percentile (n= 84, 76, 77)	0.97 (± 0.12)	0.96 (± 0.13)	0.87 (± 0.12)	

Th2 high (n=54,52,50)	1.12 (± 0.15)	1.12 (± 0.18)	0.88 (± 0.13)	
Th2 low (n= 49, 45, 44)	0.88 (± 0.15)	0.94 (± 0.17)	0.79 (± 0.17)	
Baseline EC >=150 Cells/UL (n=69, 72, 64)	1.06 (± 0.13)	1.02 (± 0.15)	0.91 (± 0.11)	
Baseline EC<150 Cells/UL (n= 34, 31, 32)	0.93 (± 0.13)	1.05 (± 0.2)	0.68 (± 0.2)	
Baseline EC >=300 Cells/UL (n= 39, 40, 35)	0.98 (± 0.17)	0.82 (± 0.2)	0.81 (± 0.15)	
Baseline EC <300 Cells/UL (N= 64, 63, 61)	1.05 (± 0.13)	1.15 (± 0.15)	0.84 (± 0.14)	
Baseline FEV1 Reversibility >=12% (n= 39, 29, 32)	1.14 (± 0.16)	0.95 (± 0.22)	0.75 (± 0.17)	
Baseline FEV1 Reversibility <12% (n= 66, 76, 67)	1.04 (± 0.13)	1.04 (± 0.14)	0.94 (± 0.13)	
2 Asthma Exacerbations (n=73, 68, 68)	1.09 (± 0.14)	1.14 (± 0.15)	0.88 (± 0.13)	
>2 Asthma Exacerbations (n= 34, 41, 33)	0.96 (± 0.14)	0.73 (± 0.2)	0.78 (± 0.16)	
With Chronic OCS Use (n= 17, 16, 16)	0.87 (± 0.29)	0.26 (± 0.26)	0.53 (± 0.19)	
Without Chronic OCS Use (n= 90, 93, 85)	1.07 (± 0.11)	1.14 (± 0.13)	0.91 (± 0.11)	

Statistical analyses

Statistical analysis title	Statistical analysis 1
Statistical analysis description: Baseline serum periostin >= median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.211
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.13
upper limit	0.6

Statistical analysis title	Statistical analysis 2
Statistical analysis description: Baseline serum periostin >= median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.397
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.21
upper limit	0.53

Statistical analysis title	Statistical analysis 3
Statistical analysis description: Baseline serum periostin < median	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.315
Method	Repeated Measure Model
Parameter estimate	Difference of LS-mean
Point estimate	0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.18
upper limit	0.56

Statistical analysis title	Statistical analysis 4
Statistical analysis description: Baseline serum periostin < median	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.166
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.11
upper limit	0.63

Statistical analysis title	Statistical analysis 5
Statistical analysis description: Baseline serum periostin >= 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.262
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.13
upper limit	0.47

Statistical analysis title	Statistical analysis 6
Statistical analysis description: Baseline serum periostin >= 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.379
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.17
upper limit	0.44

Statistical analysis title	Statistical analysis 7
Statistical analysis description: Baseline serum periostin < 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.387
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.25
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.32
upper limit	0.81

Statistical analysis title	Statistical analysis 8
Statistical analysis description: Baseline serum periostin < 25th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.303
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.26
upper limit	0.84

Statistical analysis title	Statistical analysis 9
Statistical analysis description: Baseline serum periostin >=75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.127
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.37
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.84
upper limit	0.11

Statistical analysis title	Statistical analysis 10
Statistical analysis description: Baseline serum periostin >=75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.775
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.56
upper limit	0.42

Statistical analysis title	Statistical analysis 11
Statistical analysis description: Baseline serum periostin < 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.512
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.38
upper limit	0.19

Statistical analysis title	Statistical analysis 12
Statistical analysis description: Baseline serum periostin < 75th percentile	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.404
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.12
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4
upper limit	0.16

Statistical analysis title	Statistical analysis 13
Statistical analysis description:	
Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.102
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.06
upper limit	0.69

Statistical analysis title	Statistical analysis 14
Statistical analysis description:	
Th2 high	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.116
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.08
upper limit	0.68

Statistical analysis title	Statistical analysis 15
Statistical analysis description: Th2 low	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.54
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.11
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.47
upper limit	0.25

Statistical analysis title	Statistical analysis 16
Statistical analysis description: Th2 low	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.674
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.42
upper limit	0.27

Statistical analysis title	Statistical analysis 17
Statistical analysis description: Baseline peripheral blood eosinophil count >=150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.295
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.49

Statistical analysis title	Statistical analysis 18
Statistical analysis description:	
Baseline peripheral blood eosinophil count >=150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.342
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.17
upper limit	0.49

Statistical analysis title	Statistical analysis 19
Statistical analysis description:	
Baseline peripheral blood eosinophil count < 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.406
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.18
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.24
upper limit	0.6

Statistical analysis title	Statistical analysis 20
Statistical analysis description: Baseline peripheral blood eosinophil count < 150 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.069
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.38
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.03
upper limit	0.79

Statistical analysis title	Statistical analysis 21
Statistical analysis description: Baseline peripheral blood eosinophil count >= 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.371
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.23
upper limit	0.62

Statistical analysis title	Statistical analysis 22
Statistical analysis description: Baseline peripheral blood eosinophil count >= 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.766
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.07
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.37
upper limit	0.51

Statistical analysis title	Statistical analysis 23
Statistical analysis description:	
Baseline peripheral blood eosinophil count < 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.147
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.09
upper limit	0.57

Statistical analysis title	Statistical analysis 24
Statistical analysis description:	
Baseline peripheral blood eosinophil count < 300 cells/µL	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.031
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.35
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.03
upper limit	0.68

Statistical analysis title	Statistical analysis 25
Statistical analysis description: Baseline FEV1 reversibility >= 12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.02
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.59
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.1
upper limit	1.09

Statistical analysis title	Statistical analysis 26
Statistical analysis description: Baseline FEV1 reversibility >= 12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.226
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.18
upper limit	0.77

Statistical analysis title	Statistical analysis 27
Statistical analysis description: Baseline FEV1 reversibility < 12%	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.964
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.01
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.31
upper limit	0.33

Statistical analysis title	Statistical analysis 28
Statistical analysis description: Baseline FEV1 reversibility < 12%	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.533
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.22
upper limit	0.42

Statistical analysis title	Statistical analysis 29
Statistical analysis description: 2 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.292
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.15
upper limit	0.5

Statistical analysis title	Statistical analysis 30
Statistical analysis description: 2 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.097
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.05
upper limit	0.59

Statistical analysis title	Statistical analysis 31
Statistical analysis description: > 2 but < 6 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.26
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.24
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.18
upper limit	0.67

Statistical analysis title	Statistical analysis 32
Statistical analysis description: > 2 but < 6 asthma exacerbations in the past year	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total

Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.648
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.33
upper limit	0.53

Statistical analysis title	Statistical analysis 33
Statistical analysis description: Chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.398
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.37
upper limit	0.93

Statistical analysis title	Statistical analysis 34
Statistical analysis description: Chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.327
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	-0.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.95
upper limit	0.32

Statistical analysis title	Statistical analysis 35
Statistical analysis description: Without chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.105
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.05
upper limit	0.52

Statistical analysis title	Statistical analysis 36
Statistical analysis description: Without chronic OCS use	
Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other
P-value	= 0.03
Method	Repeated measure model
Parameter estimate	Difference of LS-mean
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.03
upper limit	0.6

Secondary: Annual Asthma Exacerbation Rate (AER) by Atopic Asthma Status

End point title	Annual Asthma Exacerbation Rate (AER) by Atopic Asthma Status[73]

End point description:

Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. AER was evaluated by subgroup Atopic and Non-atopic asthma status. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all

participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[73] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: AER events/person-year				
number (confidence interval 95%)				
Atopic asthma (n=96,105,92)	0.9 (0.73 to 1.11)	0.85 (0.67 to 1.06)	0.85 (0.67 to 1.06)	
Non-atopic asthma (n=51,42,55)	0.82 (0.56 to 1.15)	1.1 (0.82 to 1.44)	1.05 (0.77 to 1.39)	

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status, chronic OCS use and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other[74]
P-value	= 0.803
Method	Poisson regression
Parameter estimate	Rate Ratio (RR)
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.62
upper limit	1.44

Notes:

[74] - Placebo Total, Tralokinumab 300 mg, Q2W - Cohort 1 - Atopic Asthma

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status, chronic OCS use and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other[75]
P-value	= 0.457
Method	Poisson regression
Parameter estimate	Rate Ratio (RR)
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.52
upper limit	1.35

Notes:

[75] - Placebo Total, Tralokinumab 300 mg, Q2/4W - Cohort 2 - Atopic Asthma

Statistical analysis title	Statistical analysis 3

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status, chronic OCS use and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other[76]
P-value	= 0.25
Method	Poisson regression
Parameter estimate	Rate Ratio (RR)
Point estimate	0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.4
upper limit	1.27

Notes:

[76] - Placebo Total, Tralokinumab 300 mg, Q2W - Cohort 1 - Non-atopic asthma

Statistical analysis title	Statistical analysis 4

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status, chronic OCS use and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other[77]
P-value	= 0.794
Method	Poisson regression
Parameter estimate	Rate Ratio (RR)
Point estimate	1.07

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.74

Notes:

[77] - Placebo Total, Tralokinumab 300 mg, Q2/4W - Cohort 2 - Non-atopic asthma

Secondary: Annual Asthma Exacerbation Rate (AER) by Chronic OCS Use

End point title	Annual Asthma Exacerbation Rate (AER) by Chronic OCS

End point description:

Annualized AER was assessed based on AER data up to Week 53. An asthma exacerbation defined as a progressive increase of asthma symptoms that does not resolve after the initiation of rescue medications and remains troublesome for the participant resulting in either 1) use of systemic corticosteroids or increase of a stable systemic maintenance dose for a duration of at least 3 consecutive days as prescribed; or 2) participant initiation of systemic corticosteroids for a duration of at least 3 consecutive days. It was considered resolved 7 days after the last dose of OCS (10 days after an injectable corticosteroid). Corticosteroids initiated after this time period were considered a separate new asthma exacerbation. AER evaluated by subgroup chronic OCS use. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies evaluable participants for this measure.

End point type	Secondary

End point timeframe:

Week 1 up to Week 53

Notes:

[78] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: AER events/person-year				
number (confidence interval 95%)				
With chronic OCS use (n=27,26,24)	2.04 (1.51 to 2.69)	2.2 (1.62 to 2.91)	1.37 (0.93 to 1.94)	
Without chronic OCS use (124,124,127)	0.68 (0.54 to 0.84)	0.74 (0.59 to 0.91)	0.81 (0.66 to 1)	

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status, chronic OCS use and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total

Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other[79]
P-value	= 0.614
Method	Poisson regression
Parameter estimate	Rate Ratio (RR)
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.59
upper limit	2.46

Notes:

[79] - Placebo Total, Tralokinumab 300 mg, Q2W - Cohort 1 - With Chronic OCS Use

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status, chronic OCS use and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other[80]
P-value	= 0.506
Method	Poisson regression
Parameter estimate	Rate Ratio (RR)
Point estimate	1.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	2.74

Notes:

[80] - Placebo Total, Tralokinumab 300 mg, Q2/4W - Cohort 2 - With Chronic OCS use

Statistical analysis title	Statistical analysis 3

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status, chronic OCS use and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2W - Cohort 1 v Placebo Total
Number of subjects included in analysis	301
Analysis specification	Pre-specified
Analysis type	other[81]
P-value	= 0.243
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.79

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.53
upper limit	1.18

Notes:

[81] - Placebo Total, Tralokinumab 300 mg, Q2W - Cohort 1 - Without Chronic OCS Use

Statistical analysis title	Statistical analysis 4

Statistical analysis description:

The 95% CI for rate ratio were estimated from the Poisson regression with treatment group, age, gender, number of exacerbations in past year (2 vs >2 but =<6), atopic asthma status, chronic OCS use and geographical region as the covariates.

Comparison groups	Tralokinumab 300 mg, Q2/4W - Cohort 2 v Placebo Total
Number of subjects included in analysis	302
Analysis specification	Pre-specified
Analysis type	other[82]
P-value	= 0.531
Method	Poisson regression
Parameter estimate	Rate Ratio
Point estimate	0.87
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.57
upper limit	1.34

Notes:

[82] - Placebo Total, Tralokinumab 300 mg, Q2/4W - Cohort 2 - Without chronic OCS use

Secondary: Change From Baseline in Percentage of Nighttime Awakening at Week 53

End point title	Change From Baseline in Percentage of Nighttime Awakening at Week 53[83]

End point description:

Scores for nighttime awakenings were generated based on the single item (question 5) that had a dichotomous response option (YES/NO). Nighttime awakenings were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated with data from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)

Notes:

[83] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage change				
arithmetic mean (standard deviation)				
Day -7 - Day -1 (Baseline) (n=151,147,145)	0.42 (± 0.43)	0.43 (± 0.43)	0.44 (± 0.42)	
Change at Day 365 - Day 371 (n=113,108,108)	-0.18 (± 0.37)	-0.23 (± 0.45)	-0.22 (± 0.43)	

Statistical analyses

No statistical analyses for this end point

Secondary: Change From Baseline in Overall Activity Limitations at Week 53

End point title	Change From Baseline in Overall Activity Limitations at Week 53[84]

End point description:

There were 3 activity limitation questions in the ASMA diary. All activity questions were scored from 0 to 4 and averaged, where the higher score indicated greater limitation. Activity limitation scores were averaged weekly for participants with at least 4 non-missing records each week. The baseline score was calculated from Day -7 to Day -1. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Day -7 - Day -1 (Baseline) and Day 365 - Day 371 (Week 53)

Notes:

[84] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: units on a scale				
arithmetic mean (standard deviation)				
Day -7 - Day -1 (Baseline) (n=151,147,145)	1.52 (± 0.9)	1.63 (± 0.85)	1.71 (± 0.86)	
Change at Day 365 - Day 371 (n=113,108,108)	-0.38 (± 0.84)	-0.48 (± 0.87)	-0.45 (± 0.81)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53

End point title	Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53[85]

End point description:

Pre- and post-bronchodilator FEV1 at clinic visits (morning) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively. Baseline for FEV1 was measured in liters.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[85] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage change in liters				
arithmetic mean (standard error)				
Pre-bronchodilator(BD): Baseline (n=147,146,146)	1.922 (± 0.056)	1.934 (± 0.059)	1.926 (± 0.05)	
Post-BD: Baseline (n=147,141,146)	2.094 (± 0.061)	2.11 (± 0.061)	2.153 (± 0.053)	
Pre-BD:Change from baseline to W53 (n=125,130,122)	9.11 (± 2.13)	2.94 (± 1.54)	2.5 (± 1.99)	
Post-BD:Change from baseline to W53(n=125,126,120)	5.98 (± 1.85)	0.18 (± 1.25)	-1.65 (± 1.39)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Percent Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53

End point title	Mean Percent Change From Baseline in Forced Expiratory Volume in 6 Second (FEV6) at Week 53[86]

End point description:

Pre- and post-bronchodilator FEV6 at clinic visits (morning) were measured. FEV6 was the maximal volume of air exhaled in the six second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively. Baseline for FEV6 was measured in liters.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[86] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage change in liters				
arithmetic mean (standard error)				
Pre-bronchodilator(BD): Baseline (n=147,146,146)	2.809 (± 0.072)	2.827 (± 0.074)	2.83 (± 0.064)	
Post-BD: Baseline (n=147,141,146)	2.981 (± 0.075)	2.98 (± 0.076)	3.055 (± 0.067)	
Pre-BD:Change from baseline to W53 (n=125,130,122)	5.75 (± 1.53)	1.1 (± 1.18)	1.06 (± 1.29)	
Post-BD:Change from baseline to W53(n=125,126,120)	3.27 (± 1.36)	-0.11 (± 1.01)	-1.16 (± 1.04)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 53

End point title	Mean Percent Change From Baseline in Forced Vital Capacity (FVC) at Week 53[87]

End point description:

Pre- and post-bronchodilator FVC at clinic visits (morning) were measured. FVC was the volume of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively. Baseline for FVC was measured in liters.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[87] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage in liters				
arithmetic mean (standard error)				
Prebronchodilator(BD): Baseline (n=147,146,146)	2.955 (± 0.075)	2.993 (± 0.079)	3.003 (± 0.069)	
Post-BD:Baseline (n=147,141,146)	3.133 (± 0.078)	3.125 (± 0.08)	3.225 (± 0.072)	
PreBD:Change from baseline to W53 (n=125,130,122)	5.43 (± 1.6)	0.46 (± 1.17)	0.87 (± 1.31)	
PostBD:Change from baseline to W53 (n=125,126,120)	2.56 (± 1.27)	-0.26 (± 1.03)	-1.51 (± 1.01)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Percent Change From Baseline in Inspiratory Capacity (IC) at Week 53

End point title	Mean Percent Change From Baseline in Inspiratory Capacity (IC) at Week 53[88]

End point description:

Pre- and post-bronchodilator IC at clinic visits (morning) were measured. IC was measured by spirometry. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively. Baseline for IC was measured in liters.

End point type	Secondary

End point timeframe:

Baseline and Week 53

Notes:

[88] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage change in liters				
arithmetic mean (standard error)				
Pre-bronchodilator(BD): Baseline (n=140,138,143)	0.023 (± 0.001)	0.023 (± 0.001)	0.022 (± 0.001)	
Post-BD: Baseline (n=140,133,135)	0.024 (± 0.001)	0.024 (± 0.001)	0.024 (± 0.001)	
Pre-BD:Change from baseline to W53 (n=108,109,103)	0.15 (± 2.21)	11.38 (± 3.71)	8.56 (± 3.42)	

Post-BD:Change from baseline to W53(n=108,109,104)	8.33 (± 3.14)	3.17 (± 2.91)	3.64 (± 3.17)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home

End point title	Mean Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 53 at Home[89]

End point description:

Pre- and post-bronchodilator FEV1 at home (morning and evening) were measured. FEV1 was the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)

Notes:

[89] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage change				
arithmetic mean (standard error)				
Change at Day 365-371: Morning (n=123,119,113)	1.67 (± 2.83)	1.7 (± 5.41)	-4.96 (± 3.27)	
Change at Day 365-371: Evening (n=119,116,111)	-2.69 (± 3.17)	-5.78 (± 3.63)	-2.83 (± 3.01)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Percent Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home

End point title	Mean Percent Change From Baseline in Peak Expiratory Flow (PEF) at Week 53 at Home[90]

End point description:

The PEF is a participant's maximum speed of expiration, as measured with a peak flow meter. Peak flow testing for PEF was performed at home (morning and evening) while sitting or standing prior to using

any medication (if needed) for asthma. Data were summarized together for 'Placebo, Q2W' and 'Placebo, Q2/4W' arms. The ITT population included all participants who were randomized into the study. Here "n" signifies participants who were evaluable for this measure for the specified time point for each arm, respectively.

End point type	Secondary

End point timeframe:

Day 1 - Day 7 (Baseline) and Day 365 - Day 371 (Week 53)

Notes:

[90] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: This endpoint was reporting data for total number of participants of both the placebo reporting group, hence not reporting statistics for all the arms in the baseline period.

End point values	Tralokinumab 300 mg, Q2W - Cohort 1	Tralokinumab 300 mg, Q2/4W - Cohort 2	Placebo Total	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	150	151	151	
Units: percentage change				
arithmetic mean (standard error)				
Change at Day 365-371: Morning (n=123,119,113)	-0.64 (± 3.26)	-2.8 (± 5.41)	-6.89 (± 3.09)	
Change at Day 365-371: Evening (n=129,116,111)	-6.62 (± 3.13)	-11.45 (± 3.33)	-4.95 (± 2.99)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events: Baseline up to Week 75	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	16.1

Reporting groups	
Reporting group title	Tralokinumab 300 mg Q2W
Reporting group description: Participants received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.	
Reporting group title	Placebo Total
Reporting group description: Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks, and participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.	
Reporting group title	Tralokinumab 300 mg Q2/4W
Reporting group description: Participants received tralokinumab 300 mg subcutaneous injection every 2 weeks (Q2W) for 12 weeks followed by every 4 weeks (Q4W) for 38 weeks (Q2/4W) for a total of 16 doses.	

Serious adverse events	Tralokinumab 300 mg Q2W	Placebo Total	Tralokinumab 300 mg Q2/4W
Total subjects affected by serious adverse events			
subjects affected / exposed	18 / 150 (12.00%)	21 / 151 (13.91%)	25 / 151 (16.56%)
number of deaths (all causes)	0	0	2
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the cervix			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Peripheral artery thrombosis			

subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Dysfunctional uterine bleeding			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Menometrorrhagia			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Allergic sinusitis			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	9 / 150 (6.00%)	6 / 151 (3.97%)	10 / 151 (6.62%)
occurrences causally related to treatment / all	1 / 13	0 / 9	2 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental poisoning			

subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle fracture			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Concussion			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excoriation			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament sprain			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar vertebral fracture			

subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	2 / 151 (1.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Testicular injury			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	2 / 151 (1.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Cardiac failure			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	2 / 151 (1.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Coronary artery disease			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sick sinus syndrome			

subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Neuropathy peripheral			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic gastropathy			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulum			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric disorder			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			

subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Osteoarthritis			
subjects affected / exposed	0 / 150 (0.00%)	2 / 151 (1.32%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rheumatoid arthritis			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amoebiasis			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Beta haemolytic streptococcal infection			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis bacterial			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Diverticulitis			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 150 (0.67%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngotonsillitis			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	3 / 150 (2.00%)	2 / 151 (1.32%)	2 / 151 (1.32%)
occurrences causally related to treatment / all	0 / 3	1 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	1 / 150 (0.67%)	0 / 151 (0.00%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 150 (0.00%)	0 / 151 (0.00%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 150 (0.67%)	1 / 151 (0.66%)	0 / 151 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	1 / 151 (0.66%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Tralokinumab 300 mg Q2W	Placebo Total	Tralokinumab 300 mg Q2/4W
Total subjects affected by non-serious adverse events			
subjects affected / exposed	133 / 150 (88.67%)	128 / 151 (84.77%)	128 / 151 (84.77%)
Vascular disorders			
Hypertension			
subjects affected / exposed	8 / 150 (5.33%)	6 / 151 (3.97%)	9 / 151 (5.96%)
occurrences (all)	8	8	10
General disorders and administration site conditions			
Administration site rash			
subjects affected / exposed	3 / 150 (2.00%)	0 / 151 (0.00%)	3 / 151 (1.99%)
occurrences (all)	13	0	3
Asthenia			
subjects affected / exposed	0 / 150 (0.00%)	6 / 151 (3.97%)	1 / 151 (0.66%)
occurrences (all)	0	8	1
Fatigue			
subjects affected / exposed	2 / 150 (1.33%)	2 / 151 (1.32%)	3 / 151 (1.99%)
occurrences (all)	4	3	4
Injection site erythema			
subjects affected / exposed	12 / 150 (8.00%)	1 / 151 (0.66%)	7 / 151 (4.64%)
occurrences (all)	58	1	15
Injection site haemorrhage			
subjects affected / exposed	1 / 150 (0.67%)	3 / 151 (1.99%)	2 / 151 (1.32%)
occurrences (all)	3	3	3
Injection site pain			
subjects affected / exposed	7 / 150 (4.67%)	15 / 151 (9.93%)	11 / 151 (7.28%)
occurrences (all)	23	90	61
Injection site pruritus			
subjects affected / exposed	8 / 150 (5.33%)	1 / 151 (0.66%)	1 / 151 (0.66%)
occurrences (all)	12	1	2
Injection site reaction			
subjects affected / exposed	7 / 150 (4.67%)	0 / 151 (0.00%)	2 / 151 (1.32%)
occurrences (all)	32	0	4
Injection site swelling			

subjects affected / exposed	2 / 150 (1.33%)	2 / 151 (1.32%)	2 / 151 (1.32%)
occurrences (all)	2	3	2
Pyrexia			
subjects affected / exposed	2 / 150 (1.33%)	6 / 151 (3.97%)	4 / 151 (2.65%)
occurrences (all)	3	10	6
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	68 / 150 (45.33%)	73 / 151 (48.34%)	58 / 151 (38.41%)
occurrences (all)	192	175	188
Cough			
subjects affected / exposed	7 / 150 (4.67%)	6 / 151 (3.97%)	8 / 151 (5.30%)
occurrences (all)	7	9	11
Dysphonia			
subjects affected / exposed	4 / 150 (2.67%)	5 / 151 (3.31%)	3 / 151 (1.99%)
occurrences (all)	4	6	4
Dyspnoea			
subjects affected / exposed	0 / 150 (0.00%)	2 / 151 (1.32%)	7 / 151 (4.64%)
occurrences (all)	0	2	16
Nasal congestion			
subjects affected / exposed	3 / 150 (2.00%)	1 / 151 (0.66%)	3 / 151 (1.99%)
occurrences (all)	3	1	3
Oropharyngeal pain			
subjects affected / exposed	3 / 150 (2.00%)	7 / 151 (4.64%)	6 / 151 (3.97%)
occurrences (all)	3	8	7
Productive cough			
subjects affected / exposed	1 / 150 (0.67%)	5 / 151 (3.31%)	1 / 151 (0.66%)
occurrences (all)	1	6	2
Rhinitis allergic			
subjects affected / exposed	11 / 150 (7.33%)	3 / 151 (1.99%)	3 / 151 (1.99%)
occurrences (all)	13	5	3
Rhinorrhoea			
subjects affected / exposed	4 / 150 (2.67%)	2 / 151 (1.32%)	1 / 151 (0.66%)
occurrences (all)	5	2	1
Upper respiratory tract inflammation			

subjects affected / exposed	3 / 150 (2.00%)	2 / 151 (1.32%)	4 / 151 (2.65%)
occurrences (all)	5	4	9
Wheezing			
subjects affected / exposed	1 / 150 (0.67%)	3 / 151 (1.99%)	1 / 151 (0.66%)
occurrences (all)	1	4	2
Psychiatric disorders			
Depression			
subjects affected / exposed	3 / 150 (2.00%)	2 / 151 (1.32%)	6 / 151 (3.97%)
occurrences (all)	3	2	6
Insomnia			
subjects affected / exposed	0 / 150 (0.00%)	4 / 151 (2.65%)	1 / 151 (0.66%)
occurrences (all)	0	4	1
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	3 / 150 (2.00%)	2 / 151 (1.32%)	4 / 151 (2.65%)
occurrences (all)	6	8	4
Fall			
subjects affected / exposed	1 / 150 (0.67%)	3 / 151 (1.99%)	2 / 151 (1.32%)
occurrences (all)	3	4	2
Foot fracture			
subjects affected / exposed	0 / 150 (0.00%)	4 / 151 (2.65%)	2 / 151 (1.32%)
occurrences (all)	0	4	2
Ligament sprain			
subjects affected / exposed	0 / 150 (0.00%)	2 / 151 (1.32%)	5 / 151 (3.31%)
occurrences (all)	0	2	6
Rib fracture			
subjects affected / exposed	3 / 150 (2.00%)	1 / 151 (0.66%)	3 / 151 (1.99%)
occurrences (all)	3	2	3
Nervous system disorders			
Dizziness			
subjects affected / exposed	2 / 150 (1.33%)	9 / 151 (5.96%)	3 / 151 (1.99%)
occurrences (all)	3	17	3
Headache			
subjects affected / exposed	17 / 150 (11.33%)	17 / 151 (11.26%)	17 / 151 (11.26%)
occurrences (all)	38	36	22
Migraine			

subjects affected / exposed	1 / 150 (0.67%)	3 / 151 (1.99%)	1 / 151 (0.66%)
occurrences (all)	2	14	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 150 (0.67%)	4 / 151 (2.65%)	0 / 151 (0.00%)
occurrences (all)	1	4	0
Eye disorders			
Conjunctivitis			
subjects affected / exposed	5 / 150 (3.33%)	0 / 151 (0.00%)	3 / 151 (1.99%)
occurrences (all)	5	0	3
Conjunctivitis allergic			
subjects affected / exposed	3 / 150 (2.00%)	2 / 151 (1.32%)	2 / 151 (1.32%)
occurrences (all)	3	2	2
Eye pruritus			
subjects affected / exposed	2 / 150 (1.33%)	0 / 151 (0.00%)	3 / 151 (1.99%)
occurrences (all)	2	0	3
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 150 (0.67%)	9 / 151 (5.96%)	1 / 151 (0.66%)
occurrences (all)	1	12	3
Abdominal pain upper			
subjects affected / exposed	1 / 150 (0.67%)	3 / 151 (1.99%)	2 / 151 (1.32%)
occurrences (all)	4	4	2
Constipation			
subjects affected / exposed	3 / 150 (2.00%)	4 / 151 (2.65%)	2 / 151 (1.32%)
occurrences (all)	3	5	2
Diarrhoea			
subjects affected / exposed	5 / 150 (3.33%)	12 / 151 (7.95%)	7 / 151 (4.64%)
occurrences (all)	7	19	10
Dyspepsia			
subjects affected / exposed	0 / 150 (0.00%)	5 / 151 (3.31%)	0 / 151 (0.00%)
occurrences (all)	0	5	0
Gastritis			
subjects affected / exposed	1 / 150 (0.67%)	4 / 151 (2.65%)	2 / 151 (1.32%)
occurrences (all)	1	5	2
Gastrooesophageal reflux disease			

subjects affected / exposed	4 / 150 (2.67%)	6 / 151 (3.97%)	2 / 151 (1.32%)
occurrences (all)	4	6	2
Nausea			
subjects affected / exposed	2 / 150 (1.33%)	7 / 151 (4.64%)	3 / 151 (1.99%)
occurrences (all)	7	15	4
Toothache			
subjects affected / exposed	3 / 150 (2.00%)	2 / 151 (1.32%)	0 / 151 (0.00%)
occurrences (all)	3	2	0
Vomiting			
subjects affected / exposed	4 / 150 (2.67%)	8 / 151 (5.30%)	1 / 151 (0.66%)
occurrences (all)	6	20	2
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	3 / 150 (2.00%)	2 / 151 (1.32%)	0 / 151 (0.00%)
occurrences (all)	3	6	0
Dermatitis contact			
subjects affected / exposed	1 / 150 (0.67%)	2 / 151 (1.32%)	2 / 151 (1.32%)
occurrences (all)	1	2	2
Pruritus			
subjects affected / exposed	7 / 150 (4.67%)	4 / 151 (2.65%)	3 / 151 (1.99%)
occurrences (all)	7	4	3
Pruritus generalised			
subjects affected / exposed	3 / 150 (2.00%)	4 / 151 (2.65%)	1 / 151 (0.66%)
occurrences (all)	3	7	2
Rash			
subjects affected / exposed	1 / 150 (0.67%)	2 / 151 (1.32%)	3 / 151 (1.99%)
occurrences (all)	1	3	3
Urticaria			
subjects affected / exposed	2 / 150 (1.33%)	5 / 151 (3.31%)	2 / 151 (1.32%)
occurrences (all)	2	6	2
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	10 / 150 (6.67%)	6 / 151 (3.97%)	9 / 151 (5.96%)
occurrences (all)	15	8	11
Back pain			

subjects affected / exposed	8 / 150 (5.33%)	9 / 151 (5.96%)	10 / 151 (6.62%)
occurrences (all)	11	11	12
Muscle spasms			
subjects affected / exposed	5 / 150 (3.33%)	2 / 151 (1.32%)	6 / 151 (3.97%)
occurrences (all)	8	2	6
Musculoskeletal chest pain			
subjects affected / exposed	2 / 150 (1.33%)	2 / 151 (1.32%)	1 / 151 (0.66%)
occurrences (all)	2	2	1
Musculoskeletal pain			
subjects affected / exposed	0 / 150 (0.00%)	4 / 151 (2.65%)	3 / 151 (1.99%)
occurrences (all)	0	4	3
Myalgia			
subjects affected / exposed	6 / 150 (4.00%)	1 / 151 (0.66%)	8 / 151 (5.30%)
occurrences (all)	7	1	11
Pain in extremity			
subjects affected / exposed	2 / 150 (1.33%)	5 / 151 (3.31%)	8 / 151 (5.30%)
occurrences (all)	2	6	9
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	2 / 150 (1.33%)	5 / 151 (3.31%)	3 / 151 (1.99%)
occurrences (all)	2	6	4
Bronchitis			
subjects affected / exposed	27 / 150 (18.00%)	22 / 151 (14.57%)	20 / 151 (13.25%)
occurrences (all)	44	48	27
Cystitis			
subjects affected / exposed	2 / 150 (1.33%)	4 / 151 (2.65%)	1 / 151 (0.66%)
occurrences (all)	2	4	1
Gastroenteritis			
subjects affected / exposed	7 / 150 (4.67%)	9 / 151 (5.96%)	6 / 151 (3.97%)
occurrences (all)	9	9	6
Herpes zoster			
subjects affected / exposed	1 / 150 (0.67%)	3 / 151 (1.99%)	1 / 151 (0.66%)
occurrences (all)	1	3	1
Influenza			
subjects affected / exposed	11 / 150 (7.33%)	13 / 151 (8.61%)	14 / 151 (9.27%)
occurrences (all)	13	15	15

Lower respiratory tract infection			
subjects affected / exposed	3 / 150 (2.00%)	4 / 151 (2.65%)	0 / 151 (0.00%)
occurrences (all)	3	5	0
Nasopharyngitis			
subjects affected / exposed	35 / 150 (23.33%)	40 / 151 (26.49%)	26 / 151 (17.22%)
occurrences (all)	57	83	62
Oral candidiasis			
subjects affected / exposed	6 / 150 (4.00%)	3 / 151 (1.99%)	2 / 151 (1.32%)
occurrences (all)	6	5	2
Pharyngitis			
subjects affected / exposed	6 / 150 (4.00%)	9 / 151 (5.96%)	11 / 151 (7.28%)
occurrences (all)	9	15	18
Pneumonia			
subjects affected / exposed	2 / 150 (1.33%)	3 / 151 (1.99%)	3 / 151 (1.99%)
occurrences (all)	2	3	3
Respiratory tract infection			
subjects affected / exposed	6 / 150 (4.00%)	3 / 151 (1.99%)	1 / 151 (0.66%)
occurrences (all)	10	4	1
Rhinitis			
subjects affected / exposed	5 / 150 (3.33%)	9 / 151 (5.96%)	8 / 151 (5.30%)
occurrences (all)	5	10	9
Sinusitis			
subjects affected / exposed	5 / 150 (3.33%)	10 / 151 (6.62%)	8 / 151 (5.30%)
occurrences (all)	5	15	10
Upper respiratory tract infection			
subjects affected / exposed	20 / 150 (13.33%)	18 / 151 (11.92%)	20 / 151 (13.25%)
occurrences (all)	36	28	25
Urinary tract infection			
subjects affected / exposed	11 / 150 (7.33%)	9 / 151 (5.96%)	8 / 151 (5.30%)
occurrences (all)	16	19	8
Viral infection			
subjects affected / exposed	0 / 150 (0.00%)	1 / 151 (0.66%)	4 / 151 (2.65%)
occurrences (all)	0	1	5
Metabolism and nutrition disorders			
Hyperglycaemia			

subjects affected / exposed occurrences (all)	0 / 150 (0.00%) 0	3 / 151 (1.99%) 4	2 / 151 (1.32%) 2

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 February 2012	The overall reason for the amendment was to include the following changes: 1) there were multiple minor changes to the design and inclusion- and exclusion criteria to add additional clarity, 2) the ACQ cut-point for uncontrolled asthma in Asthma Control Questionnaire and effect of tralokinumab on Patient Reported Outcomes was updated with the correct cut-point of >= 1.5, 3) recruitment of participants from Japan was included to meet the requirements of the Japanese Agency, Pharmaceutical and Medical Devices Agency (PMDA), 4) primary endpoint, chronic oral corticosteroid (OCS) use was added as a potential covariate.
11 October 2012	The overall reason for the amendment was to include the following changes: 1) Study abstract was amended to describe an increased alpha significance level for the primary endpoint, 2) The text was amended to describe the evaluable population for PK to include all subjects who received at least one dose of investigational product and had at least one detectable PK sample. Pharmacokinetic parameters were not computed for the CSR because of the sparse sampling PK scheme. The description of the per protocol population was also clarified to include all subjects who had no major protocol violations, completed the treatment period, and had received at least 80% of the intended doses of investigational product during the treatment period.
26 February 2013	The overall reason for the amendment was to include the following changes: 1) changed medical monitor, 2) included interim analysis as a formal analysis, and included unblinding procedures for the interim analysis.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported